Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Exostosin glycosyltransferase 1 (EXT1) is a membrane-bound enzyme localized to the Golgi apparatus, responsible for catalyzing the polymerization of heparan sulfate chains by alternately adding N-acetylglucosamine and glucuronic acid units to growing proteoglycans. EXT1 usually functions as a heterodimeric complex with EXT2, forming an obligate assembly essential for normal heparan sulfate biosynthesis. EXT1 is regarded as a putative tumor suppressor, and mutations in its gene cause hereditary multiple exostoses, a disorder marked by benign bone tumors (osteochondromas), as well as other skeletal malformations in syndromes such as Trichorhinophalangeal syndrome type II. EXT1 is bi-functional, containing both GlcA-transferase and GlcNAc-transferase domains, but its GlcA-transferase activity is indispensable for the formation of heparan sulfate chains, and most disease-causing mutations cluster in its catalytic domain. The enzyme participates in key developmental and cellular processes, including regulation of cell signaling, angiogenesis, and blood coagulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Exostosin glycosyltransferase 1 (EXT1).